NCT07403539 Speech Learning and Speech Production in Parkinson's Disease
| NCT ID | NCT07403539 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Parkinson's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-27 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-01-27 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Parkinson's disease, a common movement disorder that results from a breakdown in the brain, often leads to challenges with talking, but less is known about the relationship between difficulties with talking and difficulties with learning to understand speech. By linking these two abilities in individuals with Parkinson's disease using a precision medicine approach, this project seeks to build a basis for new therapies that help people with Parkinson's disease both understand better and speak more clearly.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Parkinson's disease * Native speaker of North American English * Use a drug that includes levodopa * Resident of the United States Exclusion Criteria: * Any history of language, hearing or speech disorder outside of Parkinson's disease * Other gross neurological impairment such as Alzheimer's disease or stroke * Significant hearing loss and/or use of a hearing aid or cochlear implant
Frequently Asked Questions
Who can join the NCT07403539 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07403539 currently recruiting?
Yes, NCT07403539 is actively recruiting participants. Visit ClinicalTrials.gov or contact State University of New York at Buffalo to inquire about joining.
Where is the NCT07403539 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT07403539 clinical trial?
NCT07403539 is sponsored by State University of New York at Buffalo. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.